KROS News and Press, Keros Therapeutics Inc. From 12/04/20

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...

LEXINGTON, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

Gainers: Alterity Therapeutics (ATHE) +120%, Outset Medical (OM) +17%, Keros Therapeutics (KROS) +9%, Inovio Pharmaceuticals (INO) +10%, Fulgent Genetics (FLGT) +14%.Losers: RAPT Therapeutics (RAPT) -46%, IMAC Holdings (IMAC) -10%, BioNTech (B...

LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

Keros Therapeutics (KROS) has priced its public offering of 2.6M common shares at $50.00/share, for expected gross proceeds of $130M.Underwriters' over-allotment is an additional 390K shares. Jefferies, SVB Leerink and Piper Sandler are acting as joint book-running managers. H.C. Wainwright &...

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

Keros Therapeutics (KROS) files for a proposed underwritten public offering of 2.25M shares of its common stock. Price, size and terms have not yet been determined.Underwriters will have an option to purchase additional up to 337,500 shares.Stock -4.46% AH.Previously: Keros The...

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and muscu...

Keros Therapeutics (KROS): Q3 GAAP EPS of -$0.60 misses by $0.01.Cash and cash equivalents of $133.8M.Press Release For further details see: Keros Therapeutics EPS misses by $0.01

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients sufferi...